Racial, ethnic and sex disparity in acute heart failure patients with COVID-19: A nationwide analysis

Anas Hashem1, Amani Khalouf1, Mohamed Salah Mohamed2

  • 1Department of Internal Medicine, Rochester General Hospital, Rochester, NY, USA.

Heliyon
|August 19, 2024
PubMed

Insights

This study found significant racial and sex disparities in outcomes for patients hospitalized with acute heart failure (AHF) and COVID-19. Hispanic males faced the highest mortality risk, highlighting critical areas for targeted interventions in AHF care.

Area of Science:

  • Cardiology
  • Infectious Diseases
  • Health Disparities

Background:

  • Patients with acute heart failure (AHF) exacerbation are at increased risk of complications during COVID-19 infection.
  • Limited data exists on racial, ethnic, and sex disparities in AHF patients with COVID-19.

Purpose of the Study:

  • To evaluate the impact of race, ethnicity, and sex on in-hospital outcomes for AHF patients with COVID-19.
  • Utilize data from the National Inpatient Sample (NIS) for comprehensive analysis.

Main Methods:

  • Extracted data from the NIS (2020) for hospitalizations with AHF and COVID-19 diagnoses.
  • Employed ICD-10-CM codes for patient identification.
  • Utilized multivariable logistic regression to examine associations between demographics and outcomes.

Main Results:

  • Analysis of 158,530 weighted AHF hospitalizations with COVID-19.
  • Hispanic males had the highest odds of in-hospital mortality (aOR 1.27) compared to White males.
  • Black males showed increased odds of cardiac arrest (aOR 1.54) and AKI (aOR 1.36), with lower odds for PCI and ventilation.

Conclusions:

  • Male sex is linked to higher in-hospital mortality in White and Black patients with AHF and COVID-19.
  • Hispanic males exhibit the highest mortality risk in this patient cohort.
  • Findings underscore the need to address racial and sex disparities in AHF management during pandemics.
Abstract

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
405
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.4K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
324